Saturday, October 31, 2026

First Foundation Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 15, 2020

First Foundation Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. United Community Banks, Inc.

21.2% sales growth and 8.6% return on equity

United Community Banks, Inc. sales growth this year is expected to be 16.4% and 1.7% for next year.

Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 533.87M for the twelve trailing months.

United Community Banks, Inc.'s sales growth for the next quarter is 21.2%. The company's growth estimates for the present quarter and the next is a negative 4.9% and 34.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.6%.

United Community Banks, Inc.'s Stock Top and Bottom Yearly Value

United Community Banks, Inc.'s stock is valued at $0.00 at 10:57 EST, below its 52-week low of $14.95.

United Community Banks, Inc.'s Moving Average

United Community Banks, Inc.'s value is under its 50-day moving average of $24.20 and under its 200-day moving average of $20.01.

2. First Foundation Inc.

14.2% sales growth and 12.04% return on equity

First Foundation Inc. sales growth this year is expected to be 17.5% and 2.4% for next year.

Year-on-year quarterly revenue growth grew by 29.4%, now sitting on 234.63M for the twelve trailing months.

First Foundation Inc.'s sales growth for the next quarter is 14.2%. The company's growth estimates for the present quarter and the next is 29.4% and 41.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.04%.

First Foundation Inc.'s Stock Top and Bottom Yearly Value

First Foundation Inc.'s stock is valued at $18.85 at 10:57 EST, below its 52-week high of $20.24 and way higher than its 52-week low of $8.01.

First Foundation Inc.'s Moving Average

First Foundation Inc.'s value is above its 50-day moving average of $17.23 and way higher than its 200-day moving average of $15.65.

3. Capital City Bank Group

28.1% sales growth and 12.48% return on equity

Capital City Bank Group sales growth this year is anticipated to be 36.3% and a negative 2.3% for next year.

Year-on-year quarterly revenue growth grew by 49.5%, now sitting on 188.94M for the twelve trailing months.

Capital City Bank Group's sales growth for the next quarter is 28.1%. The company's growth estimates for the current quarter and the next is a negative 2% and 76%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.48%.

Capital City Bank Group's Stock Top and Bottom Yearly Value

Capital City Bank Group's stock is valued at $25.55 at 10:57 EST, way below its 52-week high of $30.95 and way higher than its 52-week low of $15.61.

Capital City Bank Group's Moving Average

Capital City Bank Group's worth is way above its 50-day moving average of $23.16 and way above its 200-day moving average of $20.82.

4. BioDelivery Sciences International, Inc.

14.1% sales growth and 18.1% return on equity

BioDelivery Sciences International, Inc. sales growth this year is expected to be 37.3% and 27.7% for next year.

Year-on-year quarterly revenue growth grew by 30.1%, now sitting on 145.94M for the twelve trailing months.

BioDelivery Sciences International, Inc.'s sales growth for the next quarter is 14.1%. The company's growth estimates for the present quarter and the next is 700% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.1%.

BioDelivery Sciences International, Inc.'s Stock Top and Bottom Yearly Value

BioDelivery Sciences International, Inc.'s stock is valued at $4.31 at 10:57 EST, way under its 52-week high of $7.21 and way above its 52-week low of $2.85.

BioDelivery Sciences International, Inc.'s Moving Average

BioDelivery Sciences International, Inc.'s value is way higher than its 50-day moving average of $3.73 and higher than its 200-day moving average of $4.14.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com